Loading
Journal of Cancer Immunology
ISSN: 2689-968X
Sanjay K. Srivastava
Texas Tech University Health Sciences Center, USA
Clutch Control: Changing the Speed and Direction of CAR-T Cell Therapy
Emerging Potential of Plant Virus Nanoparticles (PVNPs) in Anticancer Immunotherapies
Humanized Chimeric Antigen Receptor (CAR) T cells
The aim of Journal of Cancer Immunology is to publish exciting discoveries on interactive immunology of deadly disease called “Cancer”. The incredible influence of immune system on transformation and growth of tumour has always influenced basic and advanced investigations on cancer. The journal is established with the aim of reporting current updates to cancer research community. Journal features original and promising discoveries in cancer immunology as research, review, novel cases and case series, editorials, correspondence and perspectives after single blind peer review process.
Higher Frequency and Poor Prognosis with COVID-19 Associated Cytokine Storm among Cancer Patients: Between Two Fires
At the end of 2019, the world faced a new disease, COVID-19 caused by SARS-Cov-2 and became a pandemic within few weeks. The fact that COVID-19 spreads very quickly and has
significant morbidity and mortality had devastating effects all over the world.
Can Butein be a Future Candidate for the Treatment of Advance Metastatic Thyroid Cancer?
The incidence and prevalence of papillary thyroid cancer (PTC) are increasing worldwide and it is the 5th most common endocrine cancer in females.
Performance of the Tyrer-Cuzick 8 Breast Cancer Risk Model Across Races: A Review
The Tyrer-Cuzick (TC) model is a breast cancer risk assessment tool that provides women with their risk of developing breast cancer based on genetic and personal factors. The most recent version of the TC model, TC8, is the first version to include breast density as a risk factor for breast cancer.
Clutch Control: Changing the Speed and Direction of CAR-T Cell Therapy
The adoptive transfer of T cells expressing chimeric antigen receptors (CAR-T cells) has revolutionized the treatment of hematological malignancies, providing unmatched clinical responses in adults and children with relapsed or refractory B cell malignancies.
Molecular Iodine Misconceptions: A Novel Formulation Approach to Topical Iodine
My team of chemists have formulated molecular iodine (I2) so it can be studied independent of other iodine species.The initial impetus for this effort was to allow for a higher concentration of biocidal I2 that would not evaporate into the atmosphere when applied to skin.
A Surprising Benefit of Cysteine Capping for Antibody Drug Conjugates
Antibody-drug conjugates (ADCs), combining the best features of monoclonal antibodies and small molecule drugs, are considered the “guided missiles” for cancer therapy, with eleven FDA-approved products. Yet the ADC modality still presents a huge challenge to drug developers, especially for targeting tumors with low abundance and/or heterogeneity of tumor-associated antigens.
Expanding the Cancer Neoantigen Peptide Repertoire beyond In silico Tools
CD8+ cytotoxic T cells recognise and kill cancer cells that present immunogenic peptides bound to the cell surface major histocompatibility complex class I (MHC-I) molecules.
SHP2 Inhibition as a Promising Anti-cancer Therapy: Function in Tumor Cell Signaling and Immune Modulation
The SHP2 phosphatase consists of one protein tyrosine phosphatase catalytic domain (PTP domain), two tandem Src homology 2 (SH2) domains (N-SH2 and C-SH2), and a C-terminal tail with two tyrosine phosphorylation sites (Tyr542 and Tyr580)
Small-molecule Interferon Inducers for Cancer Immunotherapy Targeting Non-T cell-inflamed Tumors
Since the discovery of escaping mechanism of tumor from negative immune regulation, the paradigm of drug discovery for anti-cancer agents has been dramatically shifted to cancer immunotherapy (e.g., dendritic cell therapy, CAR-T cell therapy, or antibody therapy) by stimulating patient’s immune system to treat cancer.
Emerging Strategies to Attack Polyploid Cancer Cells
While cells with a 2n complement of chromosomes are defined as diploid, cells that possess greater than 2n are referred to as polyploid.
Mitochondria Autoimmunity and MNRR1 in Breast Carcinogenesis: A Review
Recently, Aras et al. reported that MNRR1, a nuclear DNA (nDNA)-encoded mitochondrial antigen, promotes cancer cell migration and the development of metastasis as a proof of concept supporting the participation of mitochondrial autoimmunity in breast carcinogenesis.
Inference of Clonal Copy Number Alterations from RNASequencing Data
Tissues are composed of various types of interacting cells [1]. To understand the cellular organization and function in tissues, it is necessary to identify all of the different cell types and the locations of these different cell types within tissue structures.
Emerging Potential of Plant Virus Nanoparticles (PVNPs) in Anticancer Immunotherapies
Plant virus nanoparticles (PVNPs) are increasingly recognized and studied for use in biomedical applications. PVNPs include plant virions with self-assembled capsid protein coats (PC) that encapsulate the virus genome, and virus-like particles (VLPs), a capsid without the viral genome.
Humanized Chimeric Antigen Receptor (CAR) T cells
In 1989, researchers proposed an intricate strategy in the field of adoptive cell therapy (ACT). Using the T-cell receptor (TCR) as a template, they replaced the coding sequence for the Vα and Vβ chains with the antigen- recognition domains from an antibody (VH and VL chains).
Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
Bladder cancer is one of the most common and expensive cancers in the United States, with an expected 81,400 new cases and 17,980 deaths in 2020 alone. The incidence is increased among white men and diagnoses often occur in the 7th decade of life.
Cervical Cancer Prevalence in sub-Saharan Africa and HPV Vaccination Policy: A Public Health Grand Challenge?
“Women are not dying because of diseases we cannot treat. They are dying because societies have yet to make the decision that their lives are worth saving.”
Immunogenic Cell Death: A Step Ahead of Autophagy in Cancer Therapy
Cell Death has long been considered to be an inevitable part of the life cycle of a cell and hence, considered a familiar consequence of cellular life.
SHP2 Inhibition as a Promising Anti-cancer Therapy: Function in Tumor Cell Signaling and Immune Modulation
The SHP2 phosphatase consists of one protein tyrosine phosphatase catalytic domain (PTP domain), two tandem Src homology 2 (SH2) domains (N-SH2 and C-SH2), and a C-terminal tail with two tyrosine phosphorylation sites (Tyr542 and Tyr580)
Clutch Control: Changing the Speed and Direction of CAR-T Cell Therapy
The adoptive transfer of T cells expressing chimeric antigen receptors (CAR-T cells) has revolutionized the treatment of hematological malignancies, providing unmatched clinical responses in adults and children with relapsed or refractory B cell malignancies.
Can Butein be a Future Candidate for the Treatment of Advance Metastatic Thyroid Cancer?
The incidence and prevalence of papillary thyroid cancer (PTC) are increasing worldwide and it is the 5th most common endocrine cancer in females.
Emerging Potential of Plant Virus Nanoparticles (PVNPs) in Anticancer Immunotherapies
Plant virus nanoparticles (PVNPs) are increasingly recognized and studied for use in biomedical applications. PVNPs include plant virions with self-assembled capsid protein coats (PC) that encapsulate the virus genome, and virus-like particles (VLPs), a capsid without the viral genome.
Humanized Chimeric Antigen Receptor (CAR) T cells
In 1989, researchers proposed an intricate strategy in the field of adoptive cell therapy (ACT). Using the T-cell receptor (TCR) as a template, they replaced the coding sequence for the Vα and Vβ chains with the antigen- recognition domains from an antibody (VH and VL chains).
Cervical Cancer Prevalence in sub-Saharan Africa and HPV Vaccination Policy: A Public Health Grand Challenge?
“Women are not dying because of diseases we cannot treat. They are dying because societies have yet to make the decision that their lives are worth saving.”
Expanding the Cancer Neoantigen Peptide Repertoire beyond In silico Tools
CD8+ cytotoxic T cells recognise and kill cancer cells that present immunogenic peptides bound to the cell surface major histocompatibility complex class I (MHC-I) molecules.
Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.